|Bid||42.11 x 1000|
|Ask||42.12 x 900|
|Day's Range||41.35 - 44.49|
|52 Week Range||38.00 - 72.96|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||34.58|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.57|
Avanos Medical Inc NYSE:AVNSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for AVNS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AVNS are favorable with net inflows of $71.98 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Changes to the current ON-Q* pump bolus device reflect feedback from customers and consumers to increase provider and patient satisfaction ALPHARETTA, Ga. , April 3, 2019 /PRNewswire/ -- Avanos Medical, ...
Nevro Corp. (NVRO) is among a host of public and private companies marketing or developing medical devices to treat pain. Warning! GuruFocus has detected 2 Warning Signs with NVRO. Medical device companies that can help reduce opioid use promise to be rewarded handsomely and merit the attention of savvy investors.
ALPHARETTA, Ga. , March 6, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody , chief executive officer, will present at the Barclays Global Healthcare Conference on ...
COOLIEF* Cooled RF superior to hyaluronic acid injection in a study of knee osteoarthritis patients. ALPHARETTA, Ga., March 4, 2019 /PRNewswire/ -- Avanos Medical, Inc. (AVNS) today announced that its study comparing COOLIEF* Cooled Radiofrequency to hyaluronic acid (HA) in the management of knee pain achieved its primary endpoint with a statistically significant improvement in knee osteoarthritis patients experiencing at least 50 percent reduction in knee pain at 6 months after treatment (p
ALPHARETTA, Ga. , Feb. 27, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Steve Voskuil , chief financial officer, will present at the Raymond James 40 th Annual Institutional ...
ALPHARETTA, Ga. , Feb. 26, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2018 results. "2018 was a year of continued momentum and achievement, ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small-caps and large-caps are wildly popular amongRead More...
ALPHARETTA, Ga., Feb. 12, 2019 /PRNewswire/ -- Avanos Medical, Inc. (AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full-year 2018 and its 2019 outlook on Tuesday, Feb. 26 at 9 a.m. ET. The conference call will be hosted by Joe Woody, chief executive officer, and Steve Voskuil, senior vice president and chief financial officer. To join the live conference call, dial 877-240-5772 in the United States.
ALPHARETTA, Ga. , Jan. 3, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody , chief executive officer, will present at the 37 th Annual J.P. Morgan Healthcare Conference ...
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
ALPHARETTA, Ga. , Dec. 17, 2018 /PRNewswire/ -- Avanos Medical, Inc. today announced that David Ball has been appointed senior vice president, global supply chain & procurement. In this role, Ball will ...
ALPHARETTA, Ga., Dec. 10, 2018 /PRNewswire/ -- Avanos Medical, Inc. (AVNS) is pleased to announce it has been selected as one of eight winners of the FDA's Opioid Addiction Innovation Challenge. The FDA launched the challenge in May 2018 to spur the development of medical devices and solutions to help combat the growing epidemic of opioid misuse and abuse. Avanos was selected as one of eight winners among more than 250 submissions from medical device companies and/or developers.
CEO of Avanos Medical Inc (NYSE:AVNS) Joseph Fralin Woody bought 3,500 shares of AVNS on 11/28/2018 at an average price of $43.35 a share.
Data from Avanos Medical offers guidance to understanding long-term pain relief seen in cooled radiofrequency versus standard techniques. ALPHARETTA, Ga. , Nov. 16, 2018 /PRNewswire/ -- Avanos Medical, ...